Ginkgo Bioworks Holdings Inc (DNA)
0.7631
-0.16
(-17.05%)
USD |
NYSE |
May 10, 12:15
Ginkgo Bioworks Holdings Revenue (TTM): 251.46M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 251.46M |
| September 30, 2023 | 314.98M |
| June 30, 2023 | 325.95M |
| March 31, 2023 | 390.00M |
| December 31, 2022 | 477.71M |
| September 30, 2022 | 527.92M |
| Date | Value |
|---|---|
| June 30, 2022 | 539.13M |
| March 31, 2022 | 438.14M |
| December 31, 2021 | 313.84M |
| September 30, 2021 | 197.40M |
| June 30, 2021 | 133.09M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
133.09M
Minimum
Jun 2021
539.13M
Maximum
Jun 2022
355.42M
Average
325.95M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Agenus Inc | 156.31M |
| Teladoc Health Inc | 2.619B |
| Sarepta Therapeutics Inc | 1.403B |
| Ultragenyx Pharmaceutical Inc | 442.59M |
| Apellis Pharmaceuticals Inc | 524.07M |